

Aditya N. Bhosale

(404) 647-9262 | adityanb@sas.upenn.edu | <https://www.linkedin.com/in/adityanbhosale>

EDUCATION

University of Pennsylvania *B.A in Economics & Computer Science* **Expected Graduation – May 2027**
Relevant Coursework: Big Data Analytics, Multivar. Calculus, Statistics, Accounting, Finance, Economics of Life Sciences Markets
Cumulative GPA: 3.76
Skills / Tools: Solidity, Python, TypeScript, JavaScript, SQL, Foundry, React, Next.js, Node.js

PROJECTS

Dual-Layer On-Chain Liquidity Protocol – *Solidity, Foundry, TypeScript, React, Base, Ethereum* *January 2026 – Present*

- Designed & deployed a permissioned ERC-3643 SPV token on Ethereum Sepolia, paired with an LS-LMSR automated market maker on Base Sepolia for on-chain price discovery on event-triggered real-world assets
- Implemented scoring-rule pricing in Solidity using PRBMath UD60x18 fixed-point standard for exp/ln operations, deployed live with simulated trade history executing through the contract
- Engineered an algorithmic seed-and-retreat market maker mechanism to address the cold-start liquidity problem in long-tailed prediction markets, gating retreat dynamics on credentialed-trader volume accumulation

WORK EXPERIENCE

Leerink Partners – Investment Banking – Biopharma Coverage **New York, NY**
Incoming 2027 Summer Analyst (M&A Group) *June 2027 – August 2027*

Logos Global Management – Long/Short Public Equities – Smid-Cap Biotech **New York, NY**
Spring-Term Analyst *February 2026 – Present*

University College London **London, UK**
Summer Research Intern *June 2025 – August 2025*

- Wrote commentary paper discussing the use of Black-Scholes options pricing in stepwise asset valuation
- Interviewed 10+ early-stage biotech founders, physicians, and biotech operators on managerial decision making trends

Ruella Lab (Perelman School of Medicine – Center for Cell Immunotherapy) **Philadelphia, PA**
Undergraduate Researcher *September 2022 – May 2025*

- Co-authored paper in *Science Translational Medicine* (STM) developing a novel restructuring of CAR-T to target IGHV4-34 BCR for B-Cell Lymphoma and Lupus using in-vitro and in-vivo humanized mouse models developed in lab
- Ran 50+ western blots, flow cytometry, killing assays, and viral titrations for paper studying epigenetic regulators (EZH2/Tazemetostat) in T-Cells and histone methylation (American Society of Hematology publication, 2025)

Wharton Venture Lab's Snider Consulting **Philadelphia, PA**
Senior Consultant *October 2024 – Present*

- Advised a preclinical dermatology-focused biotech startup via physician interviews and competitor landscape analysis
- Developed comps-based pricing analysis for clinical-stage med-tech company developing wearable stroke detection devices

Penn Undergraduate Biotech Society (PUBS) Consulting Division **Philadelphia, PA**
Project Leader *January 2025 – Present*

- F25: Led project for Orna Therapeutics (prior to acquisition by Eli Lilly) on potential pharmaceutical partners for the company's circular-RNA based CAR-T platform
- S25: Consulted for Pfizer's Partnerships and M&A Division on an analysis of out-licensing opportunities across therapeutic areas and modalities with the firm's internal clinical pipeline

Wharton Undergraduate Healthcare Club – Investments Team **Philadelphia, PA**
Investment Associate *October 2024 – Present*

- Developing lead-asset/valuation pitch for Denali Therapeutics (NAS: DNLI) including detailed scientific/market analysis, and DCF/revenue builds for DNLI's lead assets (DNL310, DNL151) using financial databases and equity research reports
- Presented DNLI deck in-person to healthcare teams at Goldman Sachs, Citi, Lazard, Evercore ISI, and RA Cap (12/10/2025)

Harvard Medical School / Brigham & Women's Hospital (PORTAL Group) **Cambridge, MA**
Policy Research Fellow *January 2025 – May 2025*

- Wrote a retrospective economic data analysis of biosimilar market uptake trends and pricing affected by policy surrounding abbreviated approval pathways (U.S.C §262), IP Laws, and market exclusivity regulations

AWARDS, PUBLICATIONS, & INTERESTS

Awards: 2025 Taco Bell Live Más Scholar (\$10,000), 2024 Y-Prize Finalist (\$1,500 Seed Funding), Wharton Innovation Fund Grant Winner, MIT Innovation Hub Incubator Program,